Department of Nuclear Medicine and Endocrine Oncology, Institute Gustave Roussy, University of Paris-Sud, Villejuif, France.
Thyroid. 2012 Aug;22(8):832-8. doi: 10.1089/thy.2012.0081.
Patients with differentiated thyroid cancer (DTC) who have a suspicious recurrent or persistent disease based on an elevated serum thyroglobulin (Tg) or Tg antibodies (TgAb) are usually referred for empiric radioiodine ((131)I) administration to localize and treat the disease. The aim of this retrospective monocentric study was to assess the sensitivity of postempiric (131)I whole-body scan (WBS) compared to 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in such patients who had an initial normal postablation WBS.
Among 47 consecutive patients with DTC who had a normal postablation WBS and were referred for empiric (131)I administration, 34 patients (12M, 22F; mean age 53 years) underwent FDG PET/CT and form the basis of this report: 23 patients had persistently elevated serum Tg levels, 10 had elevated Tg levels observed during follow-up after they initially became under 1 ng/mL, and 1 had appearance of TgAb during follow-up. Postempiric (131)I WBS and FDG PET/CT were analyzed by independent readers.
A total of 75 lesions were found in 23 patients, distributed in 36 organs. Lesions were located in the neck (30), lungs (28), mediastinum (11), and bones (6). The sensitivities for the detection of individual lesions and for the diagnosis of metastatic organs were 88% and 97% for PET/CT and 16% and 22% for WBS, respectively (p<0.01). PET/CT was abnormal in 22 patients, among which 5 also had an abnormal postempiric (131)I WBS. There was only one patient with an abnormal postempiric (131)I WBS and a normal FDG PET/CT. This patient underwent two further (131)I administrations, with the last WBS being normal and the last stimulated Tg level being undetectable. Other patients were either treated with surgery, or classified as radioactive iodine refractory and treated with levothyroxine suppressive therapy or tyrosine kinase inhibitors.
In patients with suspicious recurrence based on the Tg level after a normal postablation WBS, FDG PET/CT is the preferred scintigraphic method to localize disease rather than postempiric (131)I WBS. Empiric (131)I administration may be used only in patients who do not have a significant FDG uptake.
根据甲状腺球蛋白(Tg)或 Tg 抗体(TgAb)升高,怀疑分化型甲状腺癌(DTC)患者有复发性或持续性疾病,通常会进行经验性放射性碘((131)I)治疗以定位和治疗疾病。本回顾性单中心研究的目的是评估初始甲状腺消融后全身扫描(WBS)正常的患者,在经验性(131)I 全身扫描后(131)I 全身扫描(WBS)的敏感性与 18-氟脱氧葡萄糖(FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)相比。
在 47 例初始甲状腺消融后 WBS 正常且接受经验性(131)I 治疗的 DTC 连续患者中,34 例患者(12 例男性,22 例女性;平均年龄 53 岁)进行了 FDG PET/CT 检查,作为本报告的基础:23 例患者持续存在血清 Tg 水平升高,10 例患者在最初低于 1ng/mL 后随访期间 Tg 水平升高,1 例患者在随访期间出现 TgAb。独立的读者分析了经验性(131)I WBS 和 FDG PET/CT。
23 例患者共发现 75 个病灶,分布于 36 个器官。病变位于颈部(30)、肺部(28)、纵隔(11)和骨骼(6)。单独检测病灶和诊断转移性器官的敏感性,PET/CT 为 88%和 97%,WBS 为 16%和 22%(p<0.01)。22 例患者的 PET/CT 异常,其中 5 例也有经验性(131)I WBS 异常。仅有 1 例患者经验性(131)I WBS 异常而 FDG PET/CT 正常。该患者接受了两次进一步的(131)I 治疗,最后一次 WBS 正常,最后一次刺激 Tg 水平无法检测。其他患者接受了手术治疗,或被归类为放射性碘难治性,并接受了甲状腺素抑制治疗或酪氨酸激酶抑制剂治疗。
在初始甲状腺消融后 WBS 正常且 Tg 水平升高的可疑复发患者中,FDG PET/CT 是定位疾病的首选闪烁成像方法,而不是经验性(131)I WBS。仅在没有明显 FDG 摄取的患者中使用经验性(131)I 治疗。